HCW Biologics (HCWB) Stock Price, News & Analysis

Company Overview

HCW Biologics, Inc. is a clinical-stage biopharmaceutical company focused on the development of antigen-specific immunotherapies for autoimmune and inflammatory diseases. The company’s proprietary intradermal delivery platform is designed to induce immune tolerance by presenting disease-relevant antigens directly to skin-resident dendritic cells. This targeted approach aims to modulate pathogenic immune responses while preserving overall immune function, with an initial focus on systemic lupus erythematosus (SLE).

At the core of HCW Biologics’ pipeline is its lead candidate, HCB101, which is currently in Phase II clinical trials for patients with moderate to severe SLE. Additional programs include preclinical immunotherapies for multiple sclerosis and rheumatoid arthritis, each leveraging the same antigen-specific tolerance technology. Preclinical data have demonstrated promising safety and biological activity, supporting the company’s strategy to expand its portfolio into other autoimmune indications.

Founded in 2016 by immunologist Dr. Hong-Chi Wang, HCW Biologics is headquartered in San Diego, California, with research collaborations spanning North America, Europe and Asia. The company has established partnerships with leading academic institutions to advance its clinical programs and refine its delivery technology. This global footprint supports HCW Biologics’ ambition to address significant unmet needs in autoimmunity and inflammatory disease worldwide.

HCW Biologics is led by President and Chief Executive Officer Dr. Ping Lin, who brings over two decades of biopharmaceutical leadership experience, and Chief Scientific Officer Dr. Maria Chen, a veteran immunologist. Under this management team, the company continues its clinical development efforts, seeks strategic collaborations, and prepares for potential commercialization of its novel immunotherapies. HCW Biologics remains committed to delivering safe, effective treatments that restore immune balance in patients living with chronic autoimmune diseases.

Key Stats

• Today's Range: $4.36 to $4.90
• 50-Day Range: $3.75 to $10.05
• 52-Week Range: $3.55 to $100.80
• Volume: 1.26 million shs
• Average Volume: 287,703 shs
• Market Capitalization: $6.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Buy

HCW Biologics Stock Analysis - MarketRank™

HCW Biologics scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

HCW Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

HCW Biologics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of HCW Biologics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HCW Biologics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.16% of the float of HCW Biologics has been sold short.

Short Interest Ratio / Days to Cover

HCW Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HCW Biologics has recently increased by 1,073.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HCW Biologics does not currently pay a dividend.

Dividend Growth

HCW Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.16% of the float of HCW Biologics has been sold short.

Short Interest Ratio / Days to Cover

HCW Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HCW Biologics has recently increased by 1,073.85%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, HCW Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $305,032.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

42.70% of the stock of HCW Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.96% of the stock of HCW Biologics is held by institutions.

HCWB Stock Analysis - Frequently Asked Questions

How have HCWB shares performed this year?

HCW Biologics' stock was trading at $17.8440 at the start of the year. Since then, HCWB stock has decreased by 74.8% and is now trading at $4.50.

How were HCW Biologics' earnings last quarter?

HCW Biologics Inc. (NASDAQ:HCWB) issued its earnings results on Thursday, May, 15th. The company reported ($0.05) earnings per share (EPS) for the quarter.

When did HCW Biologics' stock split?

Shares of HCW Biologics reverse split on Friday, April 11th 2025.The 1-40 reverse split was announced on Tuesday, April 1st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did HCW Biologics IPO?

HCW Biologics (HCWB) raised $45 million in an IPO on Tuesday, July 20th 2021. The company issued 5,600,000 shares at a price of $8.00 per share. EF Hutton acted as the underwriter for the IPO and Revere Securities was co-manager.

How do I buy shares of HCW Biologics?

Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HCW Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HCWB
• CIK: 1828673
• Web: www.hcwbiologics.com
• Phone: 954-842-2024
• Fax: 954-842-2037
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HCW Biologics: $35.00
• High Price Target: $35.00
• Low Price Target: $35.00
• Potential Upside/Downside: +677.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($23.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.02 million
• Net Margins: -1,712.94%
• Pretax Margin: -1,713.01%
• Return on Equity: N/A
• Return on Assets: -90.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $2.57 million
• Price / Sales: 2.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.08) per share
• Price / Book: -0.74

Miscellaneous

• Outstanding Shares: 1,440,000
• Free Float: 825,000
• Market Cap: $6.48 million
• Optionable: Not Optionable
• Beta: 0.65